Ameriprise Financial Inc. Acquires 9,847 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Ameriprise Financial Inc. lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 223,036 shares of the medical research company's stock after acquiring an additional 9,847 shares during the quarter. Ameriprise Financial Inc. owned 0.44% of Charles River Laboratories International worth $41,173,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Charles River Laboratories International by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock worth $1,136,938,000 after purchasing an additional 60,497 shares in the last quarter. Wellington Management Group LLP lifted its stake in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after acquiring an additional 335,658 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Charles River Laboratories International by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares in the last quarter. Finally, Ariel Investments LLC raised its position in shares of Charles River Laboratories International by 18.9% during the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after acquiring an additional 169,640 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Stock Down 3.3%

Shares of Charles River Laboratories International stock traded down $4.82 during trading hours on Wednesday, hitting $139.20. 1,595,641 shares of the company's stock traded hands, compared to its average volume of 978,001. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The stock has a 50 day simple moving average of $137.41 and a 200-day simple moving average of $165.78. The company has a market cap of $6.84 billion, a PE ratio of 928.00, a PEG ratio of 4.54 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.27 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CRL. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a research report on Monday, March 3rd. Barclays upped their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price objective for the company in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group downgraded Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $172.31.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the company's stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO James C. Foster bought 6,075 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).